In a new op-ed for Drug Discovery World, Conscience CEO Peng Fu and Communications Lead Estrid Jakobsen argue that the biggest opportunities for progress in drug discovery lie not only in new technologies, but in reimagining how science itself is organized. They explore how open science, creative collaboration, and alternative incentive models can help the field overcome rising costs, long timelines, and the limits of a patent-first mindset. Drawing lessons from history and current initiatives like Conscience’s CACHE challenges, the piece calls for a shift toward a more resilient, risk-sharing ecosystem that rewards openness and collective progress.
